| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.0038 | 1 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |